×
About 3,140 results

ALLMedicine™ Hypophosphatemia Center

Research & Reviews  1,413 results

Experience with the targeted next-generation sequencing in the diagnosis of hereditary ...
https://doi.org/10.1515/jpem-2020-0624
Journal of Pediatric Endocrinology & Metabolism : JPEM; Turan I, Erdem S et. al.

Apr 14th, 2021 - Hereditary Hypophosphatemic Rickets (HHR) is a heterogeneous group of disorders characterized by hypophosphatemia. Although the X-linked dominant HHR is the most common form, the genetic etiology of HHR is variable. Recently, developed next-genera...

Hypophosphatemia in people living with HIV: No benefit when switching from TDF to TAF.
https://doi.org/10.1097/QAD.0000000000002905
AIDS (London, England); Sandmann L, Stoll M et. al.

Apr 8th, 2021 - Treatment with tenofovir disoproxil fumarate (TDF) has been associated with hypophosphatemia mainly due to injury of the renal proximal tubulus. Studies on the impact of tenfovir alafenamid (TAF) on phosphate homeostasis in PLHIV are limited. Prom...

Bone Mineral Disease After Kidney Transplantation.
https://doi.org/10.1007/s00223-021-00837-0 10.1056/NEJM199912023412303 10.2215/CJN.01510506 10.1097/MNH.0b013e3283546ee0 10.1016/j.nefro.2016.03.004 10.2215/CJN.03920808 10.1111/ajt.16457 10.1016/j.transproceed.2009.06.073 10.1111/j.1399-0012.2011.01524.x 10.1093/ndt/13.suppl_3.94 10.2215/CJN.11371015 10.1016/j.semnephrol.2012.12.019 10.1016/j.transproceed.2005.12.065 10.1111/j.1399-0012.2007.00690.x 10.1111/j.1600-6143.2005.00938.x 10.1111/j.1600-6143.2009.02792.x 10.1093/ndt/gfh925 10.1016/j.transproceed.2007.07.079 10.1093/ndt/gfm270 10.1093/ndt/gfl583 10.1097/TP.0b013e3182530699 10.1097/SLA.0b013e3181728a2d 10.1681/ASN.2015060622 10.1111/nep.12801 10.1016/j.ijsu.2017.06.029 10.1111/hdi.12639 10.1046/j.1523-1755.2001.00755.x 10.1111/j.1399-3046.2010.01405.x 10.1097/TP.0b013e318264fc08 10.2215/CJN.01310308 10.1111/j.1440-1797.2010.01234.x 10.1093/ndt/13.10.2605 10.1016/S0272-6386(99)70045-4 10.1053/j.ajkd.2010.11.024 10.5414/CNP63087 10.1056/NEJM199108223250804 10.1016/j.kint.2016.10.008 10.1681/ASN.2018060656 10.2215/CJN.09950818 10.1359/jbmr.2001.16.10.1863 10.1016/j.kint.2017.04.006 10.1097/01.TP.0000131990.13277.28 10.1210/en.2003-0990 10.1097/00007890-199702150-00009 10.1002/jcb.21411 10.1016/j.bone.2004.07.013 10.1046/j.1523-1755.1999.00589.x 10.1007/s12020-014-0312-0 10.1093/ndt/gfh128 10.1111/ajt.12425 10.1159/000187765 10.1053/ajkd.2000.8289 10.1007/s00198-004-1653-y 10.1210/jcem.83.11.5249 10.1097/TP.0b013e31817c13e1 10.1046/j.1523-1755.2003.00938.x 10.1097/TP.0b013e31828eead8 10.1002/jbm4.10067 10.1016/j.kint.2018.12.024 10.1097/TP.0b013e3181a6bbda 10.1111/j.1600-6143.2008.02423.x 10.1056/NEJMcp1800214 10.1097/01.ASN.0000016082.70875.36 10.1111/j.1523-1755.2004.00432.x 10.1097/TP.0b013e3181a23837 10.1159/000446863 10.1136/bmj.h3783 10.1007/s00198-015-3465-7 10.1007/s00198-010-1197-2 10.1097/TP.0b013e3181dc13d0 10.1056/NEJMoa0809493 10.1002/jbmr.403 10.1111/ajt.13692 10.1097/TP.0000000000001547 10.1007/s00198-016-3534-6 10.1111/j.1600-6143.2008.02327.x
Calcified Tissue International; Torregrosa JV, Ferreira AC et. al.

Mar 25th, 2021 - Chronic kidney disease-mineral bone disorder (CKD-MBD) after kidney transplantation is a mix of pre-existing disorders and new alterations. The final consequences are reflected fundamentally as abnormal mineral metabolism (hypercalcemia, hypophosp...

see more →

Drugs  125 results see all →

Clinicaltrials.gov  1,569 results

Experience with the targeted next-generation sequencing in the diagnosis of hereditary ...
https://doi.org/10.1515/jpem-2020-0624
Journal of Pediatric Endocrinology & Metabolism : JPEM; Turan I, Erdem S et. al.

Apr 14th, 2021 - Hereditary Hypophosphatemic Rickets (HHR) is a heterogeneous group of disorders characterized by hypophosphatemia. Although the X-linked dominant HHR is the most common form, the genetic etiology of HHR is variable. Recently, developed next-genera...

Hypophosphatemia in people living with HIV: No benefit when switching from TDF to TAF.
https://doi.org/10.1097/QAD.0000000000002905
AIDS (London, England); Sandmann L, Stoll M et. al.

Apr 8th, 2021 - Treatment with tenofovir disoproxil fumarate (TDF) has been associated with hypophosphatemia mainly due to injury of the renal proximal tubulus. Studies on the impact of tenfovir alafenamid (TAF) on phosphate homeostasis in PLHIV are limited. Prom...

Bone Mineral Disease After Kidney Transplantation.
https://doi.org/10.1007/s00223-021-00837-0 10.1056/NEJM199912023412303 10.2215/CJN.01510506 10.1097/MNH.0b013e3283546ee0 10.1016/j.nefro.2016.03.004 10.2215/CJN.03920808 10.1111/ajt.16457 10.1016/j.transproceed.2009.06.073 10.1111/j.1399-0012.2011.01524.x 10.1093/ndt/13.suppl_3.94 10.2215/CJN.11371015 10.1016/j.semnephrol.2012.12.019 10.1016/j.transproceed.2005.12.065 10.1111/j.1399-0012.2007.00690.x 10.1111/j.1600-6143.2005.00938.x 10.1111/j.1600-6143.2009.02792.x 10.1093/ndt/gfh925 10.1016/j.transproceed.2007.07.079 10.1093/ndt/gfm270 10.1093/ndt/gfl583 10.1097/TP.0b013e3182530699 10.1097/SLA.0b013e3181728a2d 10.1681/ASN.2015060622 10.1111/nep.12801 10.1016/j.ijsu.2017.06.029 10.1111/hdi.12639 10.1046/j.1523-1755.2001.00755.x 10.1111/j.1399-3046.2010.01405.x 10.1097/TP.0b013e318264fc08 10.2215/CJN.01310308 10.1111/j.1440-1797.2010.01234.x 10.1093/ndt/13.10.2605 10.1016/S0272-6386(99)70045-4 10.1053/j.ajkd.2010.11.024 10.5414/CNP63087 10.1056/NEJM199108223250804 10.1016/j.kint.2016.10.008 10.1681/ASN.2018060656 10.2215/CJN.09950818 10.1359/jbmr.2001.16.10.1863 10.1016/j.kint.2017.04.006 10.1097/01.TP.0000131990.13277.28 10.1210/en.2003-0990 10.1097/00007890-199702150-00009 10.1002/jcb.21411 10.1016/j.bone.2004.07.013 10.1046/j.1523-1755.1999.00589.x 10.1007/s12020-014-0312-0 10.1093/ndt/gfh128 10.1111/ajt.12425 10.1159/000187765 10.1053/ajkd.2000.8289 10.1007/s00198-004-1653-y 10.1210/jcem.83.11.5249 10.1097/TP.0b013e31817c13e1 10.1046/j.1523-1755.2003.00938.x 10.1097/TP.0b013e31828eead8 10.1002/jbm4.10067 10.1016/j.kint.2018.12.024 10.1097/TP.0b013e3181a6bbda 10.1111/j.1600-6143.2008.02423.x 10.1056/NEJMcp1800214 10.1097/01.ASN.0000016082.70875.36 10.1111/j.1523-1755.2004.00432.x 10.1097/TP.0b013e3181a23837 10.1159/000446863 10.1136/bmj.h3783 10.1007/s00198-015-3465-7 10.1007/s00198-010-1197-2 10.1097/TP.0b013e3181dc13d0 10.1056/NEJMoa0809493 10.1002/jbmr.403 10.1111/ajt.13692 10.1097/TP.0000000000001547 10.1007/s00198-016-3534-6 10.1111/j.1600-6143.2008.02327.x
Calcified Tissue International; Torregrosa JV, Ferreira AC et. al.

Mar 25th, 2021 - Chronic kidney disease-mineral bone disorder (CKD-MBD) after kidney transplantation is a mix of pre-existing disorders and new alterations. The final consequences are reflected fundamentally as abnormal mineral metabolism (hypercalcemia, hypophosp...

see more →

News  33 results

Burosumab Is a 'Game Changer,' Effective in All Subgroups of XLH
https://www.medscape.com/viewarticle/937820

Sep 21st, 2020 - A recently approved agent, burosumab (Crysvita), was better than placebo across a range of efficacy outcomes for 14 predefined subgroups of adults with X-linked hypophosphatemia (XLH), new research shows. The authors analyzed data from the initial...

Burosumab Is a 'Game Changer,' Effective in All Subgroups of XLH
https://www.staging.medscape.com/viewarticle/937820

Sep 21st, 2020 - A recently approved agent, burosumab (Crysvita), was better than placebo across a range of efficacy outcomes for 14 predefined subgroups of adults with X-linked hypophosphatemia (XLH), new research shows. The authors analyzed data from the initial...

Burosumab Shows Sustained Efficacy in Rare Inherited Rickets
https://www.medscape.com/viewarticle/919315

Oct 1st, 2019 - ORLANDO, Florida — Burosumab (Crysvita, Ultragenyx), an anti-FGF23 monoclonal antibody, shows long-term safety and efficacy out to almost 2 years in the treatment of X-linked hypophosphatemia (XLH), a rare, inherited form of rickets, according to ...

2018 FDA-approved new drugs
https://www.mdedge.com/obgyn/article/197634/obstetrics/2018-fda-approved-new-drugs/page/0/1?channel=52

Mar 27th, 2019 - Antilipemic agents Crysvita (burosumab-twza), which has a MW of about 147,000, is a fibroblast growth factor–blocking antibody indicated for the treatment of X-linked hypophosphatemia. In pregnant cynomolgus monkeys, doses slightly higher than the.

FGF23 Inhibitor Effective in Rare Inherited Form of Rickets
https://www.staging.medscape.com/viewarticle/904089

Oct 28th, 2018 - SAN DIEGO — For adults with X-linked hypophosphatemia (XLH), a rare inherited form of rickets, a monthly dose of burosumab (Crysvita, Kyowa Hakko Kirin and Ultragenyx Pharmaceutical) can normalize phosphorous levels and enhance bone mineralization...

see more →